Cancer stem cells may be mostly maintained by fluctuating hypoxia

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 471-473

  Sun, Qingjia ^a,b   Li, Xiaoming ^a,b   Lu, Xiuying ^a   Di, Bin ^a  

^a BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; GLYCOLYSIS; HYPOXIA; NONHUMAN; PROGENY; RISK FACTOR; STEM CELL NICHE; THERAPY RESISTANCE;

CELL HYPOXIA; CELL MOVEMENT; CELL SURVIVAL; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 79952312086     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.11.023     Document Type: Article

References (43)

1. Nature Publishing Group. Milestones. Nature Cancer 2006:S7-S23.
2. Virchow R. Cellular pathology. Arch Pathol Anat Physiol Klin Med 1855, 8:3-39.
3. Chen Y.C., Hsu H.S., Chen Y.W., et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoSONE 2008, 3:e2637. 10.1371/journal.pone. 0002637.
4. Chiou S.H., Yu C.C., Huang C.Y., et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008, 14:4085-4095.
5. Taipale J., Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001, 411:349-354.
6. Tsao J.L., Tavare S., Salovaara R., et al. Colorectal adenoma and cancer divergence: evidence of multilineage progression. Am J Pathol 1999, 154:1815-1824.
7. Christine O., Helene F., Toshitaka H., et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 2008, 68:6932-6941.
8. Lagasse E. Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Ther 2008, 15:136-142.
9. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
10. Hiroko I., Toshio S. Cancer stem cells and their niche. Cancer Sci 2009, 7:1166-1172.
11. Jin L., Hope K.J., Zhai Q., et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
12. Krause D.S., Lazarides K., von Andrian U.H., et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006, 12:1175-1180.
13. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
14. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
15. Rademakers S.E., Span P.N., Kaanders J.H.A.M., Sweep F.C.G.J., Koqel A.J.V.D., Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008, 2:41-53.
16. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003, 29:297-307.
17. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001, 21:3995-4004.
18. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
19. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472.
20. Winquist R.J., Boucher D.M., Wood M., et al. Targeting cancer stem cells for more effective therapies: taking out cancer's locomotive engine. Biochem Pharmacol 2009, 78:326-334.
21. Qing G.L., Simon M.C. Hypoxia inducible factor-2a: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 2009, 19:60-66.
22. Platet N., Liu S.Y., Atifi M.E., et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007, 258:286-290.
23. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
24. Cahill D.P., Kinzler K.W., Vogelstein B., Lengauer C. Genetic instability and darwinian selection in tumours. Trends Genet 1999, 9:M57-M60.
25. Heffron C.C., Gallagher M.F., Guenther S., et al. Global mRNA analysis to determine a transcriptome profile of cancer stemness in a mouse model. Anticancer Res 2007, 27:1319-1324.
26. Bristow R.G., Hill R.P. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
27. Kimura H., Braun R.D., Ong E.T., et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996, 56:5522-5528.
28. Kang Y., Greaves B., Perry R.R. Effect of acute and chronic intermittent hypoxia on DNA topoisomerase IIα, expression and mitomycin C-induced DNA damage and cytotoxicity in human colon cancer cells. Biochem Pharmacol 1996, 52:669-676.
29. Rofstad E.K., Gaustad J.V., Egeland T.A.M., Mathiesen B., Galappathi K. Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer 2010, 127:1535-1546.
30. Koritzinsky M., Magagnin M.G., Beucken T.V.D., et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 2006, 25:1114-1125.
31. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinicaloutcome. Cancer Metastasis Rev 2007, 26:225-239.
32. Rofstad E.K. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000, 76:589-605.
33. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
34. Ceradini D.J., Gurtner G.C. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005, 15:57-63.
35. Onoue T., Uchida D., Begum N.M., Tomizuka Y., Yoshida H., Sato M. Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol 2006, 29:1133-1138.
36. Hermann P.C., Huber S.L., Herrler T.A.A., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
37. Zuniga R.M., Torcuator R., Jain R., et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009, 91:329-336.
38. Leenders W.P., Kusters B., Verrijp K., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004, 10:6222-6230.
39. Sakariassen P.O., Prestegarden L., Wang J., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. PNAS 2006, 44:16466-16471.
40. Thorsen F., Jirak D., Wang J., et al. Two distinct tumor phenotypes isolated from glioblastomas show different MRS characteristics. NMR Biomed 2008, 21:830-838.
41. Li Z.Z., Bao S.D., Wu Q.L., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cell Cancer Cell 2009, 15:501-513.
42. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978.
43. Cárdenas-Navia L.I., Mace D., Richardson R.A., et al. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res 2008, 68:5812-5819.